Therefore, there are no treatment options with approval based on data from patients with advanced melanoma who have progressed after one line of ICI therapy for BRAF-WT patients or two lines of therapy for BRAFV600 mutation-positive tumors. The gene discussed is BRAF; the disease is melanoma.